hyperphosphatemia

Alebund Pharmaceuticals Gains China NMPA NDA Acceptance

SHANGHAI, August 7, 2026 Alebund Pharmaceuticals announced that China’s National Medical Products Administration (NMPA) has formally accepted for review...

By cGxPwire Editor
August 8, 2026

.Clinical

Alebund Pharma Completes Phase 3 AP301 Enrollment

SHANGHAI, China – May 6, 2026 Alebund Pharmaceuticals (Jiangsu) Limited has announced the completion of patient enrollment in its...

By cGxPwire Editor
May 6, 2026

.VC Bio-Pharma

R1 Therapeutics Launches with $77.5M Series A to Advance CKD Treatment

Redwood City, CA – March 17, 2026 – R1 Therapeutics has officially emerged from stealth mode, announcing an oversubscribed...

By cGxPwire Editor
March 17, 2026

Pharma

Unicycive Therapeutics to Resubmit OLC NDA After FDA Type A Meeting

Los Altos, California, October 28, 2025 — Unicycive Therapeutics, Inc., a clinical-stage biopharmaceutical company developing treatments for kidney disease,...